Chapter 8 Interactions of Phospholipid Binding Proteins with Negatively Charged Membranes. β2-Glycoprotein I as a Model Mechanism

Advances in Planar Lipid Bilayers and Liposomes

Volumn 8, Issue C, 2008, Pages 243-273

  Sodin Šemrl, Snežna ^a   Frank, Mojca ^a   Ambrožič, Aleš ^a   Pavlič, Janez ^b   Šuštar, Vid ^b   Čučnik, Saša ^a   Božič, Borut ^a   Kveder, Tanja ^a   Rozman, Blaž ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 69649085452     PISSN: 15544516     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1554-4516(08)00208-1     Document Type: Review

References (104)

1. Lu J.Y., and Hofmann S.L. Thematic review series: Lipid posttranslational modifications. Lysosomal metabolism of lipid-modified proteins. J. Lipid Res. 47 (2006) 1352-1357
2. Sodin-Semrl S., and Rozman B. Beta2-glycoprotein I and its clinical significance: From gene sequence to protein levels. Autoimmun. Rev. 6 (2007) 547-552
3. Richter A., and Cleve H. Genetic variations of human serum beta2-glycoprotein I demonstrated by isoelectric focusing. Electrophoresis 9 (1988) 317-322
4. Wang S.X., Cai G.P., and Sui S.F. The insertion of human apolipoprotein H into phospholipid membranes: A monolayer study. Biochem. J. 335 Pt 2 (1998) 225-232
5. Borchman D., Harris E.N., Pierangeli S.S., and Lamba O.P. Interactions and molecular structure of cardiolipin and beta 2-glycoprotein 1 (beta 2-GP1). Clin. Exp. Immunol. 102 (1995) 373-378
6. Wurm H. Beta 2-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles. Int. J. Biochem. 16 (1984) 511-515
7. Hunt J.E., Simpson R.J., and Krilis S.A. Identification of a Region of beta2-Glycoprotein I Critical for Lipid Binding and Anti-Cardiolipin Antibody Cofactor Activity. Proc. Natl. Acad. Sci. USA. 90 (1993) 2141-2145
8. Steinkasserer A., Estaller C., Weiss E.H., Sim R.B., and Day A.J. Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I. Biochem. J. 277 Pt 2 (1991) 387-391
9. 2-glycoprotein I to phospholipids based on its crystal structure. EMBO J 18 (1999) 5166-5174
10. Mehdi H., Naqvi A., and Kamboh M.I. A hydrophobic sequence at position 313-316 (Leu-Ala-Phe-Trp) in the fifth domain of apolipoprotein H (beta2-glycoprotein I) is crucial for cardiolipin binding. Eur. J. Biochem. 267 (2000) 1770-1776
11. Cornell R.B., and Taneva S.G. Amphipathic helices as mediators of the membrane interaction of amphitropic proteins and as modulators of bilayer physical properties. Curr. Protein Pept. Sci. 7 (2006) 539-552
12. Schwarzenbacher R., Zeth K., Diederichs K., Gries A., Kostner G.M., Laggner P., and Prassl R. Crystal structure of human beta2-glycoprotein I: Implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 18 (1999) 6228-6239
13. 10-helices. Protein Eng. Des. Sel. 12 (1999) 811-814
14. Lee N.S., Brewer Jr. H.B., and Osborne Jr. J.C. Beta 2-Glycoprotein I. Molecular properties of an unusual apolipoprotein H. J. Biol. Chem. 258 (1983) 4765-4770
15. Roubey R.A. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 84 (1994) 2854-2867
16. Chung L.P., Bentley D.R., and Reid K.B. Molecular cloning and characterization of the cDNA coding for C4b-binding protein, a regulatory protein of the classical pathway of the human complement system. Biochem. J. 230 (1985) 133-141
17. Wiles A.P., Shaw G., Bright J., Perczel A., Campbell I.D., and Barlow P.N. NMR studies of a viral protein that mimics the regulators of complement activation. J. Mol. Biol. 272 (1997) 253-265
18. Casasnovas J.M., Larvie M., and Stehle T. Crystal structure of two CD46 domains reveals an extended measles virus-binding surface. EMBO. J 18 (1999) 2911-2922
19. Barlow P.N., Steinkasserer A., Norman D.G., Kieffer B., Wiles A.P., Sim R.B., and Campbell I.D. Solution structure of a pair of complement modules by nuclear magnetic resonance. J. Mol. Biol. 232 (1993) 268-284
20. Sheng Y., Kandiah D.A., and Krilis S.A. Beta2-glycoprotein I: Target antigen for "antiphospholipid" antibodies. Immunological and molecular aspects. Lupus 7 Suppl. 2 (1998) S5-S9
21. Sanghera D.K., Wagenknecht D.R., McIntyre J.A., and Kamboh M.I. Identification of structural mutations in the fifth domain of apolipoprotein H (beta 2-glycoprotein I) which affect phospholipid binding. Hum. Mol. Genet. 6 (1997) 311-316
22. Lozier J., Takahashi N., and Putnam F.W. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc. Natl. Acad. Sci. USA 81 (1984) 3640-3644
23. Canfield W.M., and Kisiel W. Evidence of normal functional levels of activated protein C inhibitor in combined Factor V/VIII deficiency disease. J. Clin. Invest. 70 (1982) 1260-1272
24. Schwick H.G., and Haupt H. Chemistry and function of human plasma proteins. Angew. Chem. Int. Ed. Engl. 19 (1980) 87-99
25. 2-glycoprotein I antibodies and the antiphospholipid syndrome. Autoimmun. Rev. 2 (2003) 229-234
26. 2-glycoprotein I revealed by small-angle X-ray scattering. J. Mol. Biol. 321 (2002) 85-97
27. Gambino R., Ruiu G., Pagano G., and Cassader M. The binding of apolipoprotein H (beta2-Glycoprotein I) to lipoproteins. Prostag. Oth. Lipid M. 57 (1999) 351-359
28. Gries A., Nimpf J., Wurm H., Kostner G.M., and Kenner T. Characterization of isoelectric subspecies of asialo-beta 2-glycoprotein I. Biochem. J. 260 (1989) 531-534
29. Kamboh M.I., Ferrell R.E., and Sepehrnia B. Genetic studies of human apolipoproteins. IV. Structural heterogeneity of apolipoprotein H (beta 2-glycoprotein I). Am. J. Hum. Genet. 42 (1988) 452-457
30. Gambino R., Ruiu G., Pagano G., and Cassader M. Qualitative analysis of the carbohydrate composition of apolipoprotein H. J. Protein Chem. 16 (1997) 205-212
31. Kiely M.L., McKnight G.S., and Schimke R.T. Studies on the attachment of carbohydrate to ovalbumin nascent chains in hen oviduct. J. Biol. Chem. 251 (1976) 5490-5495
32. Walsh M.T., Watzlawick H., Putnam F.W., Schmid K., and Brossmer R. Effect of the carbohydrate moiety on the secondary structure of beta 2-glycoprotein. I. Implications for the biosynthesis and folding of glycoproteins. Biochemistry 29 (1990) 6250-6257
33. Gambino R., Ruiu G., Pagano G., and Cassader M. Characterization of the carbohydrate structures of apolipoprotein H through concanavalin A affinity chromatography. J. Lipid Mediat. Cell Signal. 16 (1997) 11-21
34. Willems G.M., Janssen M.P., Pelsers M.M., Comfurius P., Galli M., Zwaal R.F., and Bevers E.M. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Biochemistry 35 (1996) 13833-13842
35. Schlame M., Haller I., Sammaritano L.R., and Blanck T.J. Effect of cardiolipin oxidation on solid-phase immunoassay for antiphospholipid antibodies. Thromb. Haemost. 86 (2001) 1475-1482
36. Arvieux J., Regnault V., Hachulla E., Darnige L., Berthou F., and Youinou P. Oxidation of beta2-glycoprotein I (beta2GPI) by the hydroxyl radical alters phospholipid binding and modulates recognition by anti-beta2GPI autoantibodies. Thromb. Haemost. 86 (2001) 1070-1076
37. Arvieux J., Regnault V., Hachulla E., Darnige L., Roussel B., and Bensa J.C. Heterogeneity and immunochemical properties of anti-beta2-glycoprotein I autoantibodies. Thromb. Haemost. 80 (1998) 393-398
38. d'Angeac A.D., Stefas I., Duperray C., Rucheton M., Graafland H., Montero J.L., and Chicheportiche R. Oxidation and biotinylation of beta 2 glycoprotein I glycan chains induce an increase in its affinity for anionic phospholipids similar to that obtained by the addition of anti-beta 2 glycoprotein I or anti-cardiolipin antibodies. J. Immunol. Methods 300 (2005) 160-178
39. d'Angeac A.D., Stefas I., Graafland H., De Lamotte F., Rucheton M., Palais C., Eriksson A.K., Bosc P., Rose C., and Chicheportiche R. Biotinylation of glycan chains in beta2 glycoprotein I induces dimerization of the molecule and its detection by the human autoimmune anti-cardiolipin antibody EY2C9. Biochem. J. 393 (2006) 117-127
40. Roubey R.A., Eisenberg R.A., Harper M.F., and Winfield J.B. "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J. Immunol. 154 (1995) 954-960
41. Cucnik S., Kveder T., Rozman B., and Bozic B. Binding of high-avidity anti-beta2-glycoprotein I antibodies. Rheumatology (Oxford) 43 (2004) 1353-1356
42. Sheng Y., Kandiah D.A., and Krilis S.A. Anti-beta 2-glycoprotein I autoantibodies from patients with the "antiphospholipid" syndrome bind to beta 2-glycoprotein I with low affinity: Dimerization of beta 2-glycoprotein I induces a significant increase in anti-beta 2-glycoprotein I antibody affinity. J. Immunol. 161 (1998) 2038-2043
43. Lutters B.C., Meijers J.C., Derksen R.H., Arnout J., and de Groot P.G. Dimers of beta 2-glycoprotein I mimic the in vitro effects of beta 2-glycoprotein I-anti-beta 2-glycoprotein I antibody complexes. J. Biol. Chem. 276 (2001) 3060-3067
44. 2-glycoprotein I domain V by heteronuclear magnetic resonance. J. Mol. Biol. 304 (2000) 927-939
45. de Groot G.P., Bouma B., Lutters B.C., Simmelink M.J., Derksen R.H., and Gros P. Structure-function studies on beta 2-glycoprotein I. J. Autoimmun. 15 (2000) 87-89
46. Hagihara Y., Enjyoji K., Omasa T., Katakura Y., Suga K., Igarashi M., Matsuura E., Kato H., Yoshimura T., and Goto Y. Structure and function of the recombinant fifth domain of human beta 2-glycoprotein I: Effects of specific cleavage between Lys77 and Thr78. J. Biochem. 121 (1997) 128-137
47. Ohkura N., Hagihara Y., Yoshimura T., Goto Y., and Kato H. Plasmin can reduce the function of human beta2 glycoprotein I by cleaving domain V into a nicked form. Blood 91 (1998) 4173-4179
48. Shi T., Giannakopoulos B., Iverson G.M., Cockerill K.A., Linnik M.D., and Krilis S.A. Domain V of beta2-glycoprotein I binds factor XI/XIa and is cleaved at Lys317-Thr318. J. Biol. Chem. 280 (2005) 907-912
49. Yasuda S., Atsumi T., Ieko M., Matsuura E., Kobayashi K., Inagaki J., Kato H., Tanaka H., Yamakado M., Akino M., Saitou H., Amasaki Y., et al., Nicked beta2-glycoprotein I: A marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 103 (2004) 3766-3772
50. Horbach D.A., van Oort E., Lisman T., Meijers J.C., Derksen R.H., and de Groot P.G. Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb. Haemost. 81 (1999) 87-95
51. 2 glycoprotein I in patients with leukemia and with lupus anticoagulant: Measurement with a monoclonal antibody specific for a nicked form of domain V. J. Biochem. 128 (2000) 1017-1024
52. Brighton T.A., Dai Y.P., Hogg P.J., and Chesterman C.N. Microheterogeneity of beta-2 glycoprotein I: Implications for binding to anionic phospholipids. Biochem. J. 340 Pt 1 (1999) 59-67
53. 2-glycoprotein I: Reduction of antigenicity and the structural relationship. Int. Immunol. 12 (2000) 1183-1192
54. Guerin J., Sheng Y., Reddel S., Iverson G.M., Chapman M.G., and Krilis S.A. Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome. J. Biol. Chem. 277 (2002) 2644-2649
55. Wang S.X., Cai G., and Sui S. Intrinsic fluorescence study of the interaction of human apolipoprotein H with phospholipid vesicles. Biochemistry 38 (1999) 9477-9484
56. 2-glycoprotein I with negatively charged phospholipid membranes. Biochemistry 40 (2001) 14173-14181
57. Gamsjaeger R., Johs A., Gries A., Gruber H.J., Romanin C., Prassl R., and Hinterdorfer P. Membrane binding of beta2-glycoprotein I can be described by a two-state reaction model: An atomic force microscopy and surface plasmon resonance study. Biochem. J. 389 (2005) 665-673
58. Hamdan R., Maiti S.N., and Schroit A.J. Interaction of beta2-glycoprotein 1 with phosphatidylserine-containing membranes: Ligand-dependent conformational alterations initiate bivalent binding. Biochemistry 46 (2007) 10612-10620
59. Wang S.X., Sun Y.T., and Sui S.F. Membrane-induced conformational change in human apolipoprotein H. Biochem. J. 348 Pt 1 (2000) 103-106
60. 2-glycoprotein I-dependent alterations in membrane properties. Biochim. Biophys. Acta 1509 (2000) 475-484
61. Hagihara Y., Goto Y., Kato H., and Yoshimura T. Structure and function of beta 2-glycoprotein I: With special reference to the interaction with phospholipid. Lupus 4 Suppl. 1 (1995) S3-S5
62. Ambrožič A., Čučnik S., Tomšič N., Urbanija J., Lokar M., Babnik B., Rozman B., Iglič A., and Kralj-Iglič V. Interaction of giant phospholipid vesicles containing cardiolipin and cholesterol with beta2-glycoprotein-I and anti-beta2-glycoprotein-I antibodies. Autoimmun. Rev. 6 (2006) 10-15
63. Urbanija J., Tomšič N., Lokar M., Ambrožič A., Čučnik S., Rozman B., Kanduser M., Iglič A., and Kralj-Iglič V. Coalescence of phospholipid membranes as a possible origin of anticoagulant effect of serum proteins. Chem. Phys. Lipids 150 (2007) 49-57
64. 2-glycoprotein I to negatively charged liposomes may prevent the release of daughter vesicles from the parent membrane. Eur. Biophys. J. (2008)
65. Ambrožic A., Božič B., Kveder T., Majhenc J., Arrigler V., Svetina S., and Rozman B. Budding, vesiculation and permeabilization of phospholipid membranes-evidence for a feasible physiologic role of beta2-glycoprotein I and pathogenic actions of anti-beta2-glycoprotein I antibodies. Biochim. Biophys. Acta 1740 (2005) 38-44
66. Frank M., Manček-Keber M., Kržan M., Sodin-Semrl S., Jerala R., Iglič A., Rozman B., and Kralj-Iglič V. Prevention of microvesiculation by adhesion of buds to the mother cell membrane-a possible anticoagulant effect of healthy donor plasma. Autoimmun. Rev. 7 (2008) 240-245
67. M. Frank, J. Pavliover(c, -), K. Bohinc, B. Rozman, V. Kralj-Iglič, A. Iglič, Influence of ionic strength on agglutination of like-charged phospholipid membranes induced by beta2-GPI (in preparation).
68. Harper M.F., Hayes P.M., Lentz B.R., and Roubey R.A. Characterization of beta2-glycoprotein I binding to phospholipid membranes. Thromb. Haemost. 80 (1998) 610-614
69. Wang F., Xia X.F., and Sui S.F. Human apolipoprotein H may have various orientations when attached to lipid layer. Biophys. J. 83 (2002) 985-993
70. Bevers E.M., Zwaal R.F., and Willems G.M. The effect of phospholipids on the formation of immune complexes between autoantibodies and beta2-glycoprotein I or prothrombin. Clin. Immunol. 112 (2004) 150-160
71. Zwaal R.F., and Schroit A.J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89 (1997) 1121-1132
72. Morel O., Toti F., Hugel B., and Freyssinet J.M. Cellular microparticles: A disseminated storage pool of bioactive vascular effectors. Curr. Opin. Hematol. 11 (2004) 156-164
73. VanWijk M.J., VanBavel E., Sturk A., and Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc. Res. 59 (2003) 277-287
74. Comfurius P., Senden J.M., Tilly R.H., Schroit A.J., Bevers E.M., and Zwaal R.F. Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. Biochim. Biophys. Acta 1026 (1990) 153-160
75. Sims P.J., Wiedmer T., Esmon C.T., Weiss H.J., and Shattil S.J. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: An isolated defect in platelet procoagulant activity. J. Biol. Chem. 264 (1989) 17049-17057
76. Wiedmer T., Shattil S.J., Cunningham M., and Sims P.J. Role of calcium and calpain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet factor Va receptor. Biochemistry 29 (1990) 623-632
77. Zwaal R.F., Comfurius P., and Bevers E.M. Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. Biochim. Biophys. Acta 1180 (1992) 1-8
78. Farge E., and Devaux P.F. Shape changes of giant liposomes induced by an asymmetric transmembrane distribution of phospholipids. Biophys. J. 61 (1992) 347-357
79. 2+-ATPase inhibitors. Biochemistry 34 (1995) 11625-11634
80. Khashayar F., and De Camilli P. Mechanisms of membrane deformation. Curr. Opin. Cell Biol. 15 (2003) 372-381
81. Svetina S., and Žekš B. Shape behavior of lipid vesicles as the basis of some cellular processes. Anat. Rec. 268 (2002) 215-225
82. Casciola-Rosen L., Rosen A., Petri M., and Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: Implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA. 93 (1996) 1624-1629
83. Sheetz M.P., and Singer S.J. Biological membranes as bilayer couples - molecular mechanism of drug erythrocyte interaction. Proc. Natl. Acad. Sci. USA. 71 (1974) 4457-4461
84. Svetina S., and Žekš B. Membrane bending energy and shape determination of phospholipid vesicles and red blood cels. Eur. Biophys. J. 17 (1989) 101-111
85. Berndl K., Käs J., Lipowsky R., Sackmann E., and Seifert U. Shape transformations of giant vesicles: Extreme sensitivity to bilayer asymmetry. Europhys. Lett. 13 (1990) 659-664
86. Miao L., Seifert U., Wortis M., and Dobereiner H.G. Budding transitions of fluid-bilayer vesicles: The effect of area-difference elasticity. Phys. Rev. E. 49 (1994) 5389-5407
87. Svetina S., and Žekš B. Bilayer couple as a possible mechanism of biological shape formation. Biomed. Biochim. Acta 44 (1985) 979-986
88. Meroni P.L., and Riboldi P. Pathogenic mechanisms mediating antiphospholipid syndrome. Curr. Opin. Rheumatol. 13 (2001) 377-382
89. 2-glycoprotein I antibodies in children with atopic dermatitis. Int. Immunol. 14 (2002) 823-830
90. Gomez-Gutierrez J., Rodriguez-Crespo I., Peterson D.L., and Gavilanes F. Antigenicity of hepatitis B surface antigen proteins reconstituted with phospholipids. Biochim. Biophys. Acta 1233 (1995) 205-212
91. 2-glycoprotein I in patients with antiphospholipid syndrome: Preferential recognition of the major phospholipid-binding site. Blood 98 (2001) 1889-1896
92. 2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum. 43 (2000) 65-75
93. 2-glycoprotein I in patients with antiphospholipid syndrome. Blood 99 (2002) 2499-2504
94. Hunt J., and Krilis S. The fifth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J. Immunol. 152 (1994) 653-659
95. Sheng Y., Sali A., Herzog H., Lahnstein J., and Krilis S.A. Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J. Immunol. 157 (1996) 3744-3751
96. 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 105 (2005) 1552-1557
97. Yamaguchi Y., Seta N., Kaburaki J., Kobayashi K., Matsuura E., and Kuwana M. Excessive exposure to anionic surfaces maintains autoantibody response to 2-glycoprotein I in patients with antiphospholipid syndrome. Blood 110 (2007) 4312-4318
98. Božič B., Čučnik S., Kveder T., and Rozman B. Avidity of anti-beta-2-glycoprotein I antibodies. Autoimmun. Rev. 4 (2005) 303-308
99. 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105 (2005) 1540-1545
100. Igarashi M., Matsuura E., Igarashi Y., Nagae H., Ichikawa K., Triplett D.A., and Koike T. Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. Blood 87 (1996) 3262-3270
101. George J., Gilburd B., Hojnik M., Levy Y., Langevitz P., Matsuura E., Koike T., and Shoenfeld Y. Target recognition of beta2-glycoprotein I (beta2GPI)-dependent anticardiolipin antibodies: Evidence for involvement of the fourth domain of beta2GPI in antibody binding. J. Immunol. 160 (1998) 3917-3923
102. Iverson G.M., Victoria E.J., and Marquis D.M. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc. Natl. Acad. Sci. USA 95 (1998) 15542-15546
103. Kuitunen M., Savilahti E., and Sarnesto A. Human alpha-lactalbumin and bovine beta-lactoglobulin absorption in infants. Allergy 49 (1994) 354-360
104. Proulle V., Hugel B., Guillet B., Grunebaum L., Lambert T., Freyssinet J.M., and Dreyfus M. Circulating microparticles are elevated in haemophiliacs and non-haemophilic individuals aged <18 years. Br. J. Haematol. 131 (2005) 487-489